NCT07712575 A Study of V132 in Healthy Older Participants (V132-001)
| NCT ID | NCT07712575 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Merck Sharp & Dohme LLC |
| Condition | Healthy |
| Study Type | INTERVENTIONAL |
| Enrollment | 280 participants |
| Start Date | 2026-08-12 |
| Primary Completion | 2028-06-21 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 280 participants in total. It began in 2026-08-12 with a primary completion date of 2028-06-21.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to learn about the safety and immune response to the V132 vaccine in healthy older adults.
Eligibility Criteria
Inclusion Criteria: The key inclusion criteria include but are not limited to the following: * Is in good health * Has body mass index (BMI) within 18.0 to 35.0 kg/m\^2 (inclusive) Exclusion Criteria: The key exclusion criteria include but are not limited to the following: * Has a history of invasive pneumococcal disease or known history of other culture-positive pneumococcal disease within 3 years prior to receiving study vaccination * Has received a pneumococcal polysaccharide vaccine in the previous 10 years, has received any pneumococcal conjugate vaccine at any time prior to this study
Contact & Investigator
Medical Director
STUDY DIRECTOR
Merck Sharp & Dohme LLC
Frequently Asked Questions
Who can join the NCT07712575 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 75 Years, studying Healthy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07712575 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07712575 currently recruiting?
Yes, NCT07712575 is actively recruiting participants. Contact the research team at Trialsites@msd.com for enrollment information.
Where is the NCT07712575 trial being conducted?
This trial is being conducted at Anaheim, United States, Hallandale, United States, Hollywood, United States, South Miami, United States and 5 additional locations.
Who is sponsoring the NCT07712575 clinical trial?
NCT07712575 is sponsored by Merck Sharp & Dohme LLC. The principal investigator is Medical Director at Merck Sharp & Dohme LLC. The trial plans to enroll 280 participants.